All Comments by Alexei Koudinov

  1. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro.
  2. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice.
  3. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease.
  4. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.
  5. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.
  6. Alzheimer's disease. A technical KO of amyloid-beta peptide.
  7. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
  8. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.
  9. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.
  10. The origins of Alzheimer disease: a is for amyloid.
  11. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.
  12. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins.
  13. Alzheimer's disease: genes, proteins, and therapy.
  14. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease.
  15. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.